This report was aimed at analysing the activities of three new mAbs, directed against different cell surface molecules preferentially expressed by B-CLL and other haematopoietic tumours: CD5, the transferrin receptor or a class II MHC molecule. This evidence concerns the gene CD5 and B-cell chronic lymphocytic leukemia.